Abstract
There are increasing data that suggest a role for the serine protease matriptase and its inhibitor, hepatocyte growth factor activator inhibitor-1, in the pathogenesis and progression of ovarian cancer. This review will discuss the matriptase/inhibitor system in the context of ovarian cancer and examine the possibility that this system might be a useful therapeutic and/or diagnostic target in this disease.
MeSH terms
-
Biomarkers, Tumor
-
Disease Progression
-
Enzyme Activation
-
Female
-
Humans
-
Ovarian Neoplasms / classification
-
Ovarian Neoplasms / diagnosis*
-
Ovarian Neoplasms / therapy
-
Serine Endopeptidases / analysis
-
Serine Endopeptidases / physiology*
-
Serine Proteinase Inhibitors / analysis
-
Serine Proteinase Inhibitors / physiology
-
Trypsin / analysis
-
Trypsin / physiology*
Substances
-
Biomarkers, Tumor
-
Serine Proteinase Inhibitors
-
Serine Endopeptidases
-
matriptase
-
ST14 protein, human
-
Trypsin